Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis

Linda Stein Gold, MD1; Boni Elewski, MD2; Zoe Draelos, MD3; Tina Lin, PharmD4
1Henry Ford Hospital, Detroit, MI; 2University of Alabama at Birmingham School of Medicine, Birmingham, AL; 3Dermatology Consulting Services, PLLC, High Point, NC; 4Ortho Dermatologics, Bridgewater, NJ

Abstract

Psoriasis is a chronic, immune-mediated disease that can have frequent exacerbations and remissions.2 Disease characteristics and optimal treatment strategies for psoriasis may differ between males and females.3

In two phase 3, multicenter, double-blind studies, participants were randomized (2:1) to receive HP/TAZ or vehicle lotion once-daily for 8 weeks, with a 4-week posttreatment follow-up4,5 to assess treatment success at study week 8 (Figure 1).

METHODS

METHODS

Women (n=101) and men (n=175) were included in the study; the analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).

RESULTS

Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

FIGURE 1. Overall Treatment Successa by Study Visit in Female and Male Participants (ITT Population, Pooled)

Percentage of Female Participants

Treatment Posttreatment

HP/TAZ Lotion (n=101)
Vehicle (n=45)

Female Participants

Erythema Plaque Elevation Scaling

Study Visit (Weeks)

Study Visit (Weeks)

HP/TAZ Lotion (n=175)
Vehicle (n=97)

Study Visit (Weeks)

Treatment Posttreatment

Percentage of Male Participants


ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics, Ortho Dermatologics is a division of Bausch Health US, LLC. Presented at Winter Clinical Dermatology Conference • January 17-22, 2020 • Kohala Coast, HI

REFERENCES

REFERENCES

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).

1. The analysis population included 146 female participants (HP/TAZ lotion, n=101; vehicle, n=45) and 222 male participants (HP/TAZ lotion, n=175; vehicle, n=97).
2. Efficacy

At week 8, the percentage of female and male participants with treatment success was significantly greater in the HP/TAZ group than the vehicle group (significant differences were observed by week 2 and maintained posttreatment (Figure 1)).